Fig. 6: HRC4 nebulization protects monkeys from clinical manifestation of MeV infection.
From: Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection
a Experimental design: cynomolgus monkeys (3 animals/group) were either nebulized with 3 ml of NaCl 0.9% (control group, C) or with 3 ml HRC4 peptide 4 mg/ml (experimental group, P), 24 h and 6 h before and 24 h after intra-tracheal infection with 104 PFU MeV IC323-eGFP. Blood samples were taken every 3 days for the first 16 days and fluorescence of the skin and mucosa tested at that time points. b Macroscopic manifestation of MeV infection, typical fluorescent rash observed on tongue, skin (back and chin) and palate (marked with white arrows), monitored under anesthesia using a blue light with orange filter. c Duration of the clinical signs in MeV-infected animals followed daily (dpi: days post infection). d Analysis of viremia by quantification of the percentage of GFP+ peripheral blood mononuclear cells (PBMC) in the blood by flow cytometry and MeV-specific RNA in PBMCs and in throat swabs by RT-qPCR, during the course of infection. Source data are provided as a Source Data file.
